| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abatacept for the prevention of GVHD in patients receiving mismatched unrelated transplants: a real-world analysis
|
Raghunandan, Sharmila
|
|
|
7 |
16 |
p. 4395-4399
|
artikel
|
| 2 |
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
|
Phillips, Tycel J.
|
|
|
7 |
16 |
p. 4518-4527
|
artikel
|
| 3 |
Allelic variation of KIR and HLA tunes the cytolytic payload and determines functional hierarchy of NK cell repertoires
|
Philippon, Camille
|
|
|
7 |
16 |
p. 4492-4504
|
artikel
|
| 4 |
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
|
Othman, Jad
|
|
|
7 |
16 |
p. 4539-4549
|
artikel
|
| 5 |
“Autoimmune HIT” antibodies in diagnostic samples are a potential artifact and not associated with more severe outcomes
|
Kanack, Adam J.
|
|
|
7 |
16 |
p. 4431-4434
|
artikel
|
| 6 |
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
|
Lee, Dae Hyun
|
|
|
7 |
16 |
p. 4247-4257
|
artikel
|
| 7 |
CD38 as a pan-hematologic target for chimeric antigen receptor T cells
|
Glisovic-Aplenc, Tina
|
|
|
7 |
16 |
p. 4418-4430
|
artikel
|
| 8 |
Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes
|
Pasca, Sergiu
|
|
|
7 |
16 |
p. 4660-4670
|
artikel
|
| 9 |
Characterization of the human platelet N- and O-glycome upon storage using tandem mass spectrometry
|
Rosenbalm, Katelyn E.
|
|
|
7 |
16 |
p. 4278-4290
|
artikel
|
| 10 |
Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma
|
Dean, Erin A.
|
|
|
7 |
16 |
p. 4608-4618
|
artikel
|
| 11 |
CNL and aCML are prognostically distinct: a large National Cancer Database analysis
|
Tremblay, Douglas
|
|
|
7 |
16 |
p. 4400-4402
|
artikel
|
| 12 |
Computer vision quantitation of erythrocyte shape abnormalities provides diagnostic, prognostic, and mechanistic insight
|
Foy, Brody H.
|
|
|
7 |
16 |
p. 4621-4630
|
artikel
|
| 13 |
Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report
|
Lee, Thomas D.
|
|
|
7 |
16 |
p. 4599-4607
|
artikel
|
| 14 |
Diagnosing TMAs by automated red cell morphology analyses
|
Billett, Henny H.
|
|
|
7 |
16 |
p. 4631-4632
|
artikel
|
| 15 |
Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging
|
Wright, Kyle T.
|
|
|
7 |
16 |
p. 4633-4646
|
artikel
|
| 16 |
Editorial Board
|
|
|
|
7 |
16 |
p. i
|
artikel
|
| 17 |
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
|
Major, Ajay
|
|
|
7 |
16 |
p. 4528-4538
|
artikel
|
| 18 |
Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia
|
Rankine-Mullings, Angela
|
|
|
7 |
16 |
p. 4319-4322
|
artikel
|
| 19 |
Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
|
Achini-Gutzwiller, Federica R.
|
|
|
7 |
16 |
p. 4462-4474
|
artikel
|
| 20 |
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study
|
Bhatnagar, Bhavana
|
|
|
7 |
16 |
p. 4671-4675
|
artikel
|
| 21 |
Front Matter
|
|
|
|
7 |
16 |
p. ii
|
artikel
|
| 22 |
Genomic landscape of TP53-mutated myeloid malignancies
|
Abel, Haley J.
|
|
|
7 |
16 |
p. 4586-4598
|
artikel
|
| 23 |
Greenwood M, Trahair T, Sutton R, et al. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL. Blood Adv. 2021;5(24):5574-5583.
|
|
|
|
7 |
16 |
p. 4620
|
artikel
|
| 24 |
Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy
|
Nawas, Mariam T.
|
|
|
7 |
16 |
p. 4475-4478
|
artikel
|
| 25 |
How I read an article that uses machine learning methods
|
Nazha, Aziz
|
|
|
7 |
16 |
p. 4550-4554
|
artikel
|
| 26 |
Identification of USP9X as a leukemia susceptibility gene
|
Sisoudiya, Saumya Dushyant
|
|
|
7 |
16 |
p. 4563-4575
|
artikel
|
| 27 |
Identifying experts for clinical practice guidelines: perspectives from the ASH Guideline Oversight Subcommittee
|
Byrne, Michael
|
|
|
7 |
16 |
p. 4323-4326
|
artikel
|
| 28 |
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
|
Akahoshi, Yu
|
|
|
7 |
16 |
p. 4479-4491
|
artikel
|
| 29 |
Individual phosphatidylinositol transfer proteins have distinct functions that do not involve lipid transfer activity
|
Zhao, Liang
|
|
|
7 |
16 |
p. 4233-4246
|
artikel
|
| 30 |
In-person and virtual assessment of short physical performance battery test in older adults with myeloid malignancies
|
Sanapala, Chandrika
|
|
|
7 |
16 |
p. 4414-4417
|
artikel
|
| 31 |
Longitudinal metabolic study of red blood cells from patients undergoing gender-affirming testosterone therapy
|
Roy, Micaela Kalani
|
|
|
7 |
16 |
p. 4269-4277
|
artikel
|
| 32 |
Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models
|
Hacken, Elisa ten
|
|
|
7 |
16 |
p. 4514-4517
|
artikel
|
| 33 |
Mazzara S, Travaini L, Botta F, et al. Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL. Blood Adv. 2023;7(4):630-643.
|
|
|
|
7 |
16 |
p. 4619
|
artikel
|
| 34 |
More evidence for low-dose IL-2 for chronic GVHD in children
|
Levine, John E.
|
|
|
7 |
16 |
p. 4658-4659
|
artikel
|
| 35 |
Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes
|
Schulz, Eduard
|
|
|
7 |
16 |
p. 4381-4394
|
artikel
|
| 36 |
Olutasidenib: from bench to bedside
|
Venugopal, Sangeetha
|
|
|
7 |
16 |
p. 4358-4365
|
artikel
|
| 37 |
Ontogenesis of functional platelet subpopulations from preterm and term neonates to adulthood: The PLINIUS study
|
Weiss, Lukas J.
|
|
|
7 |
16 |
p. 4334-4348
|
artikel
|
| 38 |
Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant
|
Bartlett, Allison L.
|
|
|
7 |
16 |
p. 4555-4562
|
artikel
|
| 39 |
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
|
Deng, Li-Juan
|
|
|
7 |
16 |
p. 4349-4357
|
artikel
|
| 40 |
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
|
Charalampous, Charalampos
|
|
|
7 |
16 |
p. 4371-4380
|
artikel
|
| 41 |
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial
|
Bassan, Renato
|
|
|
7 |
16 |
p. 4448-4461
|
artikel
|
| 42 |
Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
|
Roeker, Lindsey E.
|
|
|
7 |
16 |
p. 4291-4301
|
artikel
|
| 43 |
Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease
|
Wobma, Holly
|
|
|
7 |
16 |
p. 4647-4657
|
artikel
|
| 44 |
Return emergency department visits for recurrent pulmonary embolism symptoms in children and adolescents
|
Egan-Sherry, Dana
|
|
|
7 |
16 |
p. 4327-4333
|
artikel
|
| 45 |
SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb
|
Rajagopal, Vaishnavi
|
|
|
7 |
16 |
p. 4258-4268
|
artikel
|
| 46 |
Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention
|
Hamilton, Betty K.
|
|
|
7 |
16 |
p. 4505-4513
|
artikel
|
| 47 |
Telomerase-targeted therapies in myeloid malignancies
|
Waksal, Julian A.
|
|
|
7 |
16 |
p. 4302-4314
|
artikel
|
| 48 |
Tetraspanins set the stage for bone marrow microenvironment–induced chemoprotection in hematologic malignancies
|
Quagliano, Anthony
|
|
|
7 |
16 |
p. 4403-4413
|
artikel
|
| 49 |
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
|
Villa, Diego
|
|
|
7 |
16 |
p. 4576-4585
|
artikel
|
| 50 |
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
|
Bachy, Emmanuel
|
|
|
7 |
16 |
p. 4435-4447
|
artikel
|
| 51 |
Use of letermovir in umbilical cord blood transplantation based on risk scores
|
Rivera Franco, Monica M.
|
|
|
7 |
16 |
p. 4315-4318
|
artikel
|
| 52 |
Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis
|
Masetti, Riccardo
|
|
|
7 |
16 |
p. 4366-4370
|
artikel
|
Tijdschrift beschrijving